September 4, 2024 03:18 PM EDT

Moderna’s mpox vaccine outperforms approved version in preclinical study

Max Bayer

Pharma Reporter

Preclinical data suggest that Moderna’s mpox vaccine could be superior to other alternatives currently approved, according to new research published Wednesday.

Scientists

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Moderna’s mpox vaccine outperforms approved version in preclinical study

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

Ex-Kite leaders step in at Kyverna as CEO exits after landing year's second-biggest IPO

Pfizer tees up Phase 3 test in weight management — but in an unexpected area

BioNTech rolls out Phase 2 lung cancer data as VEGF bispecifics take center stage

Immatics loses Bristol Myers' support on Phase 1 bispecific T cell engager

Breaking down silos with a new quantitative approach to drug development

Mod­er­na’s mpox vac­cine out­per­forms ap­proved ver­sion in pre­clin­i­cal study

Pharma Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Moderna’s mpox vaccine outperforms approved version in preclinical study